|
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This activity is supported by an educational grant from
sanofi aventis
PLEASE CLICK HERE TO VIEW
THE SLIDES
(Please right-click on the link and select "Save Target As"
to download the PDF Slides on to your computer)
PLEASE CLICK HERE TO LISTEN TO THE AUDIO
(Audio and Slides
are not Synced)
PLEASE CLICK HERE FOR POST TEST AND
EVALUATION
Instructions for CME/CEU: View the presentation, answer the
post test, complete the evaluation form and submit to
keads@namcp.org.
A score of 70% must
be achieved on the post test to receive continuing education
credits. You will
have the option on the post test/evaluation page to submit your
forms electronically or by faxing them to Katie Eads at
804-747-5316. Summary
Pulmonary embolism and deep vein
thrombosis are collectively referred to as ve¬nous thromboembolism (VTE).
Pulmonary embolism is the most common prevent¬able cause of hospital
death. Pharmacologic methods to prevent VTE are safe, ef¬fective,
cost-effective, and advocated by evidence-based guidelines.
Hospitalized medical and surgical patients routinely have multiple
risk factors for VTE, but pro¬phylaxis is significantly underused.
Multiple national quality initiatives are underway to decrease the
rate of VTE during hospitalization and after discharge.
Objectives
-
Describe risk factors associated
with DVT/PE
-
Identify management methods to
reduce the possibility of DVT leading to a pulmonary embolism
-
Discuss treatment options for DVT/PE
|
Faculty: |
Darrell W. Harrington,
MD, FACP, Associate Professor of Medicine, UCLA School
of Medicine, Chief, Division of General Internal
Medicine, Harbor-UCLA Medical Center |
|
Disclosure:
|
Dr.
Harrington discloses the following relationships with
entities producing, marketing, re-selling, or
distributing Healthcare goods or services consumed by,
or used on, patients.
Research: Eisai, Pfizer-Bristol Myers Squibb, UMass
Honorarium: Eisai, GlaxoSmithKline, sanofi aventis
Advisory Board: Bristol Myers Squibb, Eisai,
GlaxoSmithKline, sanofi aventis
All presented material is independent of industry
produced content. Only material supported by published
data and evidence based guidelines is being presented. |
|
|
The NAMCP planning
committee has no real or perceived financial
relationships to disclose. |
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education to sponsor continuing medical education for physicians.
NAMCP designates this activity for a maximum of 1 AMA PRA Category I
creditsTM. Each physician should claim credit commensurate with the
extent of their participation in the activity.
The American Association of Managed Care Nurses (AAMCN) has been
approved as a provider of continuing education by the Virginia
Nurses Association (VNA). VNA is accredited as an approver of
continuing education in nursing by the American Nurses Credentialing
Center’s Commission on Accreditation. Nurses who complete this
activity will be awarded 1.0 contact hours.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
.
This activity is
supported by an educational grant from sanofi aventis
|